Aberrant regulation of RNA stability has an important role in many disease states 1, 2 . Deregulated post-transcriptional modulation, such as that governed by microRNAs targeting linear sequence elements in messenger RNAs, has been implicated in the progression of many cancer types [3] [4] [5] [6] [7] . A defining feature of RNA is its ability to fold into structures. However, the roles of structural mRNA elements in cancer progression remain unexplored. Here we performed an unbiased search for post-transcriptional modulators of mRNA stability in breast cancer by conducting whole-genome transcript stability measurements in poorly and highly metastatic isogenic human breast cancer lines. Using a computational framework that searches RNA sequence and structure space 8 , we discovered a family of GC-rich structural cis-regulatory RNA elements, termed sRSEs for structural RNA stability elements, which are significantly overrepresented in transcripts displaying reduced stability in highly metastatic cells. By integrating computational and biochemical approaches, we identified TARBP2, a double-stranded RNA-binding protein implicated in microRNA processing, as the trans factor that binds the sRSE family and similar structural elements-collectively termed TARBP2-binding structural elements (TBSEs)-in transcripts. TARBP2 is overexpressed in metastatic cells and metastatic human breast tumours and destabilizes transcripts containing TBSEs. Endogenous TARBP2 promotes metastatic cell invasion and colonization by destabilizing amyloid precursor protein (APP) and ZNF395 transcripts, two genes previously associated with Alzheimer's and Huntington's disease, respectively. We reveal these genes to be novel metastasis suppressor genes in breast cancer. The cleavage product of APP, extracellular amyloida peptide, directly suppresses invasion while ZNF395 transcriptionally represses a pro-metastatic gene expression program. The expression levels of TARBP2, APP and ZNF395 in human breast carcinomas support their experimentally uncovered roles in metastasis. Our findings establish a non-canonical and direct role for TARBP2 in mammalian gene expression regulation and reveal that regulated RNA destabilization through protein-mediated binding of mRNA structural elements can govern cancer progression.
Aberrant regulation of RNA stability has an important role in many disease states 1, 2 . Deregulated post-transcriptional modulation, such as that governed by microRNAs targeting linear sequence elements in messenger RNAs, has been implicated in the progression of many cancer types [3] [4] [5] [6] [7] . A defining feature of RNA is its ability to fold into structures. However, the roles of structural mRNA elements in cancer progression remain unexplored. Here we performed an unbiased search for post-transcriptional modulators of mRNA stability in breast cancer by conducting whole-genome transcript stability measurements in poorly and highly metastatic isogenic human breast cancer lines. Using a computational framework that searches RNA sequence and structure space 8 , we discovered a family of GC-rich structural cis-regulatory RNA elements, termed sRSEs for structural RNA stability elements, which are significantly overrepresented in transcripts displaying reduced stability in highly metastatic cells. By integrating computational and biochemical approaches, we identified TARBP2, a double-stranded RNA-binding protein implicated in microRNA processing, as the trans factor that binds the sRSE family and similar structural elements-collectively termed TARBP2-binding structural elements (TBSEs)-in transcripts. TARBP2 is overexpressed in metastatic cells and metastatic human breast tumours and destabilizes transcripts containing TBSEs. Endogenous TARBP2 promotes metastatic cell invasion and colonization by destabilizing amyloid precursor protein (APP) and ZNF395 transcripts, two genes previously associated with Alzheimer's and Huntington's disease, respectively. We reveal these genes to be novel metastasis suppressor genes in breast cancer. The cleavage product of APP, extracellular amyloida peptide, directly suppresses invasion while ZNF395 transcriptionally represses a pro-metastatic gene expression program. The expression levels of TARBP2, APP and ZNF395 in human breast carcinomas support their experimentally uncovered roles in metastasis. Our findings establish a non-canonical and direct role for TARBP2 in mammalian gene expression regulation and reveal that regulated RNA destabilization through protein-mediated binding of mRNA structural elements can govern cancer progression.
Gene expression studies, in principle, measure steady-state transcript levels. However, such measurements obscure the role of dynamic post-transcriptional programs, from splicing to nuclear export to transcript stability 9 . To study the dynamics of the RNA life cycle in cancer, we isolated transcript stability from other aspects of RNA regulation. We used a non-invasive method-based on 4-thiouridine labelling and capture 8, 10 followed by high-throughput sequencing-to determine the decay rates for roughly 13,000 transcripts expressed by the parental MDA-MB-231 (MDA) breast cancer cell line and its in vivo-selected highly metastatic MDA-LM2 subline (biological quadruplicates spanning 4 time points composed of 32 total samples). A t-test-derived statistic (t-score), ranging from 21 (more stable in parental MDA) to 1 (more stable in highly metastatic MDA-LM2), was used as a measure for differential decay rates between the two cell lines. We then employed a mutual-information-based computational approach 8 to identify the cis-regulatory elements that may mediate the differences in transcript stability observed between the metastatic MDA-LM2 cell line and its parental MDA line. We discovered a family of structural RNA stability elements, termed sRSEs, embedded in transcripts that displayed reduced stability in highly metastatic cells (Fig. 1a and Extended Data Fig. 1a ). As we show later, this broad family of GC-rich stem-loops, with a median stem length of 9 base pairs (bp) and a median loop length of 7 nucleotides, is bound by a common trans factor. Consistent with their higher decay rates in metastatic cells, sRSE-carrying transcripts displayed significantly reduced steady-state expression in metastatic MDA-LM2 cells relative to less metastatic MDA parental cells ( Fig. 1b and Extended Data Fig. 1b) . Moreover, the significantly correlated expression of these transcripts in three independent human gene-expression data sets raised the possibility of their co-regulation through a common post-transcriptional pathway mediated by this structural element (Extended Data Fig. 2a-c) .
To directly assess the transcriptome-wide functionality of the identified sRSEs, we performed an in-culture cellular titration experiment in which synthetic RNA oligonucleotides harbouring tandem instances of sRSE1, the most informative representative member of the sRSE family (Extended Data Fig. 1a ), were used as intracellular decoys that would bind the putative trans factor, preventing it from targeting endogenous transcripts 11 (Extended Data Fig. 2d ). Consistent with our hypothesis, the expression levels of endogenous sRSE-carrying transcripts were significantly upregulated in cells transfected with synthetic decoys relative to their levels in cells transfected with scrambled controls (Fig. 1c and Extended Data Fig. 2e ). These findings suggest that the sRSEbinding trans factor, when competitively titrated by the decoy, promotes transcript destabilization.
We then chose a particular sRSE, matching the motif definition of sRSE1 on a differentially destabilized transcript, for further analysis. The secondary structure of this element, determined in silico (M-fold 12 ) and in vitro through differential S1/V1 nuclease digestion sequence analysis 13 , matches that of the sRSE1 motif (Extended Data Fig. 3a) . Additionally, mCherry reporter constructs carrying this element and its modified versions in their 39 untranslated regions (UTRs) were used to test its functionality and establish the necessity of its underlying stem-loop structure (Extended Data Fig. 3b, c) . We compared mCherry-encoding transcripts (using green fluorescent protein (GFP) as an internal control) carrying four different forms of the structural element in their 39 UTR: an sRSE1 versus scrambled pair to reveal whether the element has a functional role in transcript stability and expression, and a structured versus unstructured mimetic pair to establish if its secondary structure is essential for its functionality (Fig. 1d ). This analysis revealed that this sRSE is sufficient for suppression of expression and that its structure-not simply its sequence-is the key regulatory determinant.
We next sought to identify the sRSE-binding trans factor by computationally searching for candidate RNA-binding proteins (RBPs) whose expression levels correlated with sRSE-carrying transcripts across breast cancer gene expression profiles 14 . Using this approach, we identified three candidate RBPs, namely TARBP2, HEXIM1 and PPRC1, as potential post-transcriptional regulators of this regulon based on their correlated expression (Extended Data Fig. 4a ). RNA interference (RNAi)-mediated knockdown followed by transcriptomic profiling revealed that silencing one of these RBPs, TARBP2, yielded a significant upregulation of sRSE-carrying transcripts ( Fig. 2a and Extended Data Fig. 4b) . A similar upregulation was observed upon TARBP2 knockdown in CN-LM1a cells, an in vivo-selected highly metastatic breast cancer line derived from another patient's breast tumour (CN34) 6 , and 293T kidney epithelial cells, suggesting a more general and physiological regulatory link between TARBP2 and sRSE-carrying transcripts (Extended Data Fig. 4c, d ). Importantly, the enhanced expression of this regulon was concomitant with enhanced transcript stability upon a-amanitin treatment ( Fig. 2b and Extended Data Fig. 4e ). Conversely, overexpression of TARBP2 in MDA parental cells resulted in a significant downregulation of sRSE-carrying transcripts ( Fig. 2c and Extended Data Fig. 4f) . Moreover, the gene expression profile resulting from TARBP2 knockdown in metastatic cells was significantly correlated to that obtained from in-culture cellular titration, consistent with the titration of TARBP2 upon sRSE-decoy RNA transfection (Extended Data Fig. 4g ). TARBP2, first identified on the basis of its ability to bind the double-stranded stem portions of the human immunodeficiency virus (HIV) tar RNA 15 , was subsequently found (through gel mobility-shift assays of synthetic RNA variants) to prefer double-stranded RNAs (for example, stem-loops) with high GC content 16 -closely resembling sRSE. TARBP2 was later found to have a physiological role in the cell by binding microRNA hairpin precursors on their path to maturation 17 . To biochemically assess direct binding of the sRSE by TARBP2, we performed ultraviolet radiation crosslinking and co-immunoprecipitation (HITS-CLIP 18 ) of tagged TARBP2 and found a significant enrichment of sRSE among the TARBP2 co-immunoprecipitated mRNAs ( Fig. 2d and Extended Data Fig. 5a -e). More importantly, the TARBP2-binding sites determined using HITS-CLIP enabled us to go beyond sRSE and provide a direct experimental description of the broader underlying structural elements, which we collectively termed TBSEs. TARBP2 binds both exonic and intronic TBSEs with a preference for intronic sites. TBSEs showed a high GC content along with a higher propensity to form secondary structures than expected by chance (Extended Data Fig. 5f, g ). Moreover, transcript measurements from mCherry-fused sRSE/scrambled reporters showed that sRSE-dependent transcript downregulation was abrogated in the setting of TARBP2 knockdown ( Fig. 2e and Extended Data Fig. 5h ). More importantly, while we initially used sRSE as a proxy to study the behaviour of the TARBP2 regulon in metastatic cells, TARBP2 HITS-CLIP provided us with the set of transcripts that are bound by TARBP2 in vivo that can be studied directly. These TARBP2-bound transcripts showed significant enrichment amongst the differentially destabilized transcripts in MDA-LM2 cells; they were also significantly upregulated and stabilized in the context of TARBP2 knockdown and were downregulated in cells overexpressing TARBP2 (Extended Data  Fig. 5i, j) . In vitro binding assays using purified tagged TARBP2 and short oligo-ribonucleotides also supported our in vivo observations: (1) TARBP2 directly interacts with the sRSE1 element or its structured mimetic but minimally interacts with scrambled and unstructured variants (Extended Data Fig. 6a-c) ; (2) TARBP2-mediated co-precipitation of a large randomized RNA population followed by high-throughput sequencing resulted in an enrichment for GC-rich structured RNA variants closely resembling sRSE elements (Extended Data Fig. 6d-h ). Taken together, our findings reveal that TARBP2 binds TBSEs-a family of , gold entries correspond to bins with overrepresentation of sRSEcarrying transcripts, while blue bins mark underrepresentation. Statistically significant enrichments and depletions are marked with red and dark-blue borders, respectively. The sRSEs are collectively depicted as a generic stem-loop with blue and red circles marking nucleotides with low and high GC content, respectively (black positions are unconstrained regarding the number and identity of nucleotides from these positions onward; see also Methods). Also included are mutual information (MI) values and their associated z-scores.
b, Gene expression in LM2 versus MDA cells. The significant enrichment of sRSE-carrying transcripts among genes with lower expression in metastatic MDA-LM2 cells is shown relative to the parental MDA cell line. Transcripts were sorted according to their log 2 fold-change (logFC) of their expression levels in MDA-LM2 versus MDA cells and divided into equally populated bins from lower expression in MDA-LM2 cells (left) to higher expression (right). c, In-culture titration experiment. The enrichment of sRSE-carrying transcripts among the genes upregulated (based on their log-ratio) upon transfection of decoy RNA molecules harbouring engineered sRSE1 compared to scrambled controls. d, Transcript stability quantification for mCherry (normalized to GFP as an internal control) carrying four different forms of the sRSE, namely sRSE1, structured mimetic, unstructured mimetic and scrambled control. a-Amanitin treatments at the 0 and 8 h time points followed by total RNA extraction and complementary DNA synthesis were used to estimate relative stability between variants (n 5 6 per sample per time point; two independent sets of biological triplicate). Error bars indicate standard error of the mean (s.e.m.). **P , 0.01 by a one-tailed Mann-Whitney test.
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GC-rich apical and internal stem-loop elements within endogenous transcripts-and negatively regulates their stability and expression in vivo (Extended Data Fig. 6i-k) .
Consistent with the observed downregulation of TARBP2-bound transcripts in metastatic MDA-LM2 cells, TARBP2 transcript and protein levels were found to be expressed at higher levels in MDA-LM2 and CN-LM1a cells relative to their parental lines ( Fig. 2f and Extended Data Fig. 7a ). The increased expression of TARBP2 in multiple patients' metastatic derivative lines suggested that it may have a role in metastatic progression. We also observed that primary human breast tumours that metastasized (stage IV) displayed significantly higher expression of TARBP2 relative to early stage (stages I and II) tumours, which have low metastasis rates (Extended Data Fig. 7b) .
Consistent with these clinical associations, TARBP2 knockdown significantly reduced lung metastatic colonization in CN-LM1a (,7-fold) and MDA-LM2 (,2.5-fold) cell lines as assessed by tail-vein lung colonization assays ( Fig. 3a and Extended Data Fig. 7c) . We also observed a significant reduction in the number of metastatic nodules in lungs of mice injected with TARBP2 knockdown cells ( Fig. 3b and Extended Data Fig. 7d ). These effects on metastasis were not due to enhanced growth as the in vitro proliferation rate of cells was not significantly reduced upon TARBP2 knockdown (Extended Data Fig. 7e ). TARBP2 knockdown also reduced invasiveness (,2-fold)-a phenotype required for efficient metastasis ( Fig. 3c and Extended Data Fig. 7f ). TARBP2 silencing did not reduce primary tumour growth in cells growing in the mammary fat pads of mice (Fig. 3d) . TARBP2 depletion did, however, significantly reduce orthotopic metastasis to the lungs ( Fig. 3e and Extended Data Fig. 7g ). Our findings, taken together, reveal a role for endogenous TARBP2 as a promoter of metastatic cell invasion and colonization in breast cancer.
To identify the metastasis suppressor genes that are post-transcriptionally repressed by TARBP2, we performed an unbiased analysis of the gene-expression and stability profiles of TARBP2 knockdown cells to find transcripts that are directly bound by TARBP2 and are sensitive to modulations in TARBP2 levels. We identified four transcripts that were directly bound by TARBP2 in vivo (see Extended Data Fig. 8a ) as well as substantially destabilized and downregulated in highly metastatic MDA-LM2 and CN-LM1a cells (validated through polymerase chain reaction with quantitative reverse transcription (qRT-PCR)), which express higher levels of TARBP2 than their isogenic parental lines (Extended Data Fig. 8b-d ). These genes consisted of amyloid precursor protein (APP), zinc finger protein 395 (ZNF395), the adaptor-related protein complex 2 (AP2A2), and laminin b1 (LAMB1). Importantly, these transcripts displayed both higher stability and abundance in the context of TARBP2 knockdown ( Fig. 4a and Extended Data Fig. 8e, f) . High-grade tumours, which have higher relapse rates, from three independent gene-expression compendia (N 5 821; ref. 19 ) exhibited a significantly lower aggregate expression of these four genes relative to low-grade tumours (Fig. 4b) . Additionally, patients whose tumours showed a reduced aggregate expression for these genes experienced significantly lower overall metastasis-free survival compared to those whose tumours expressed higher aggregate expression for these genes (Fig. 4c) . These clinical associations b, Transcript stability in TARBP2 knockdown versus control (MDA-LM2). The enrichment of sRSE-carrying transcripts among those whose stabilities were enhanced in TARBP2 knockdown cells. Samples taken at the 0 and 18 h time points after a-amanitin treatment were used to estimate relative stability (see Methods). c, Expression of sRSE-carrying transcripts in TARBP2 overexpression versus control (MDA). The sRSE regulon was enriched among transcripts downregulated in MDA-LM2 cells overexpressing TARBP2 (relative to GFP-transfected cells). d, Significant enrichment of sRSEs among the TARBP2-binding sites (determined using HITS-CLIP). Co-IP, coimmunoprecipitation. e, The expression levels of sRSE/scrambled-fused mCherry reporters assayed in control and TARBP2 knockdown cells (n 5 6 per sample; two independent sets of biological triplicates). f, Relative TARBP2 mRNA expression in MDA/MDA-LM2 and CN34/CN-LM1a cells determined using qRT-PCR (n 5 7 per sample; three independent sets of two biological replicates and a triplicate). Error bars indicate s.e.m. **P , 0.01 by a one-tailed Mann-Whitney test unless otherwise specified. ; n 5 8 and 6, respectively). e, Lung bioluminescence (7 days after tumour extraction) measured in vivo (photons s 21 cm 22 sr
21
; n 5 3 and 4 for shControl and shTARBP2, respectively, in an MDA-LM2 background). Error bars indicate s.e.m. *P , 0.05, **P , 0.01 by a one-tailed Mann-Whitney test unless specified otherwise.
RESEARCH LETTER
and their inverse relationship to TARBP2 transcript expression further highlight these genes' potential roles as suppressors of metastatic progression in human breast cancer and provide additional support for TARBP2 as their upstream regulator.
To identify the primary modulators of metastasis suppression among these four targets, we performed functional epistasis experiments, in which each of these genes was stably silenced in the background of TARBP2 knockdown. In both breast cancer lines, silencing APP or ZNF395 significantly enhanced metastatic colonization ( Fig. 4d and Extended Data Fig. 9a-c) as well as cellular invasion by cells depleted of TARBP2 (Fig. 4e and Extended Data Fig. 9d, e) . APP-previously implicated in Alzheimer's disease-is a membrane protein that is proteolytically cleaved to yield soluble products (such as, soluble amyloid-a peptide) 20 , while ZNF395 is a poorly characterized transcription factor involved in the transcriptional activation of the Huntington's disease gene huntingtin 21 . Consistent with these functional findings, patients whose primary breast tumours showed reduced expression levels of APP and ZNF395 experienced significantly lower survival rates than those whose tumours displayed higher levels of these genes in several independent clinical cohorts (P , 1 3 10
26
; Extended Data Fig. 9f ). These findings reveal ZNF395 and APP to be downstream functional targets of TARBP2 and to associate with survival of breast cancer patients.
To determine if amyloid peptide products could directly mediate the suppressive effects of APP mRNA on invasion, we added soluble amyloid-a and -b to MDA-LM2 cells and quantified their invasive capacity. Interestingly, only amyoid-a treatment reduced the invasiveness of cancer cells (Fig. 4f and Extended Data Fig. 10a ). Consistent with our findings, APP has also been previously implicated in ovarian cancer cell invasion 22 . Our similar observations in breast cancer metastasis suggest a more general role for APP as a suppressor of cancer invasion as well as a suppressor of metastatic progression by a metastatic cancer type, namely breast cancer.
On the other hand, transcriptomic profiling of ZNF395 knockdown cells revealed upregulation of a number of established promoters of cancer progression (Extended Data Fig. 10b Fig. 10c ). Given their well-established roles in cancer progression and metastasis, we hypothesize that ZNF395 silencing enhances metastasis in part through de-repression of these genes.
TARBP2, a component of the RISC-loading complex 17, 26 , has been previously implicated as a modest suppressor of tumour growth in Ewing's sarcoma through its role in microRNA maturation 27 . In contrast, our findings reveal TARBP2 to be a robust promoter of metastasis in breast cancer. Furthermore, the TARBP2-mediated post-transcriptional regulation of APP and ZNF395, and TARBP2-bound transcripts in general, proved to be independent of microRNA-mediated regulation as DICER knockdown did not increase transcript levels of these genes (Extended Data Fig. 10d-f ). More importantly, neither DICER silencing nor its genetic inactivation in Dicer 2/2 murine cells precluded TARBP2-mediated suppression of TARBP2-bound transcripts and APP and ZNF395 in particular, consistent with this network constituting a TARBP2-dependent and DICER-independent pathway (Extended Data Fig. 10g-i) .
Our findings establish a novel post-transcriptional regulatory network whereby TARBP2 binding of structural hairpins contained in specific metastasis suppressor transcripts leads to their destabilization (Fig. 4g) . We reveal that structural information contained in transcripts can govern cancer progression by acting as binding sites for a destabilizing RNA-binding trans factor. We also implicate the TARBP2/APP/ ZNF395 pathway in metastatic progression through loss-of-function, epistasis, and clinical pathological correlation analyses. Additionally, our findings reveal a microRNA-independent role for TARBP2 in gene expression regulation through mRNA destabilization. While we have focused on transcript stability, several other aspects of the RNA life cycle, such as alternative splicing and RNA localization, are impacted by structural RNA elements and may be systematically studied in the context of cancer progression using a similar approach. We speculate that small molecule or oligonucleotide-based interference with interactions between such trans factors and structural elements in transcripts may constitute novel routes towards therapeutic modulation of disease states.
METHODS SUMMARY
Animal experiments were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee at The Rockefeller University. See Methods for details on sequencing, computational analysis, cell culture, immunoprecipitation, western blotting, proliferation, invasion and animal studies, as well as cloning and generation of cell lines. , ExpO compendium (Gene Expression Omnibus (GEO) accession GSE2109), and GSE5460). Box plots: the bottom and the top of the box are the first and third quartile, respectively, and the central line is the median; probability density plots are superimposed. c, Kaplan-Meier curves for a compendium of breast cancer patients 19 (n 5 459) showing metastasis-free survival as a function of TARBP2 target aggregate expression. P value is based on a Mantel-Cox log-rank test. d, Bioluminescence imaging plot of lung metastasis by cells expressing shRNAs targeting one of four TARBP2 targets or a control shRNA (shControl) in an MDA-LM2 shTARBP2 background; n 5 5 in each cohort except for shZNF395, in which n 5 4. Also shown are bioluminescence images from representative mice. e, Cell invasion capacity measured for APP and ZNF395 knockdown cells (relative to shControl) in an MDA-LM2 shTARBP2 background; n 5 8 for each sample (two independent sets of quadruplicates). f, Cell invasion capacity measured for MDA-LM2 cells with exogenously added amyloid-a relative to bovine serum albumin (BSA) as control; n 5 8 for each sample (two independent sets of quadruplicates). g, Schematic of TARBP2-mediated enhancement of invasion and metastatic colonization through APP and ZNF395 transcript destabilization. Error bars indicate s.e.m. *P , 0.05, **P , 0.01, ***P , 0.001 by a one-tailed MannWhitney test. 
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METHODS
Cell culture. CN34 and MDA-MB-231 cells and their respective sublines, CNLM1a and MDA-LM2, were propagated as previously described 6 . HEK293T cells were cultured in DMEM-based media supplemented with 10% FBS, glutamine, pyruvate, penicillin, streptomycin and fungizone. RNAi and DNA transfections were performed using Lipofectamine 2000 (Invitrogen) and TransIT-293 (Mirus), respectively. Cells were regularly tested for mycoplasma contamination. RNA decay rate measurements. 4-Thio-uridine labelling and RNA preparation were performed as described elsewhere 8 for the 0, 2, 4 and 7 h time points. The collection was performed in biological quadruplicate for each cell line (32 samples total). Samples were barcoded (fourfold multiplexed) for sequencing using ScriptSeq RNA-seq Library Preparation Kit (Epicentre) and sequencing-by-synthesis was performed using the HiSeq 2000 sequencer (Illumina). Read alignment to human transcriptome (build hg19) and quantification were performed using TopHat 28 and Cufflinks 29 , respectively. For each transcript, the reported reads per kilobase per million (RPKM) values were first corrected based on the amount of labelled RNA recovered at each time-point and were then used to estimate decay rates (r 5 2ln(S t /S 0 )/t) (ref. 8) , which resulted in four decay rate measurements (biological quadruplicates) in MDA parental cells and four in MDA-LM2 cells. These values were then used to calculate the probability of a difference between the two cell lines (Student's t-test). The calculated probabilities (P) were subsequently transformed into a directional statistic for all transcripts (that is, t-score 5 s (1 2 P) , where s is the direction of the change), ranging from 21 (significantly stable in MDA-231) and 1 (significantly stable in MDA-LM2). For quantized analyses, a t-score ,20.8 threshold (,10% of transcripts) was used to mark the set of transcripts destabilized in MDA-LM2 cells. Discovering the structural cis-regulatory elements. Post-transcriptional cisregulatory elements rely on contributions from the local secondary structure as well as their underlying sequence to interact with their binding partners 8, [30] [31] [32] [33] [34] . We recently introduced a computational framework called TEISER which captures both structural and sequence information contained in RNA sequences 8 . While regulatory elements are enriched in the UTRs, many examples of RNA elements fall within the boundaries of the coding sequence. To employ an unbiased search of the transcript sequence space, we used TEISER to discover structural regulatory elements across mature transcripts (along the coding sequences as well as the 59 and 39 UTRs) that were informative of differential transcript stability measurements.
We identified a large number of GC-rich structural elements that were enriched in the transcripts destabilized in MDA-LM2 cells. Upon their identification by TEISER, informative structural elements were grouped on the basis of their similarity (defined based on conditional information ratio 35 ) and were found to be highly similar, with a conditional information ratio of less than two relative to the element with the highest mutual information value. Accordingly, TEISER classified these elements into a single family of GC-rich structural elements, named sRSE for structural RNA stability element. The element with the highest mutual information (MI) value (sRSE1; Extended Data Fig. 1 ) was subsequently used as a representative of the entire family for all transcriptome-wide analyses (in Extended Data Fig. 1 we have included sRSE1 as well as a few members of this family sorted on the basis of their similarity to sRSE1). In order to represent the entire family, which contains 318 distinct elements, we extracted all instances of all elements across the transcriptome. We then used RNAfold 36 to determine the secondary structure of the extracted sequences along with 20 bp flanking sequences. Sequences whose in silico secondary structures were capped with their corresponding structural elements with a low folding free energy (one standard deviation below the average folding energy of all extracted sequences) were labelled as sRSE instances and the host transcripts (carrying at least one such instance) were identified as the sRSEcarrying transcripts or the sRSE regulon. The extracted sRSE instances were also used to calculate the GC-content at select positions across the stem and the loop (4 bp of stem and 4 nucleotides of loop) from which a graphical representation of the entire family across the transcriptome was created (for example, Fig. 1a) . TEISER in nondiscovery mode was used to show enrichment/depletion patterns of the sRSE regulon in various types of data (for example, gene expression profiles, in-culture cellular titration experiments, knockdown profiles, and stability measurements) 8 . Hypergeometric distribution-based enrichment scores were defined as described previously 8 . To ensure that the behaviour of the entire family matches that of representative members, we have also included results in which sRSE1 was used as the most informative member in our analyses. In-culture sRSE-decoy cellular titration experiment. Decoy and scrambled sequences (Extended Data Fig. 3c ) were synthesized in vitro (IDT) and PCR amplified using forward-T7 linked primers. Capped and polyadenylated RNAs were generated using in vitro transcription (mMESSAGE mMACHINE, Ambion; poly-A polymerse, NEB). MDA-LM2 cells were then transfected with decoy and scrambled RNA molecules, in biological replicates, as detailed previously 8 . Fortyeight hours post-transfection, total RNA was collected from each sample (Norgen Biotek), labelled (TargetAmp-Nano Labelling Kit, Epicentre), and hybridized to human microarray slides (HumanHT-12, Illumina). The intensities were measured using GenomeStudio 1.0.6 (Illumina), and the Lumi package in R was used to transform and normalize signal intensities. The logFC between average decoy and scrambled signal was used as a measure of differential expression for each transcript. For quantized analyses, a logFC .0.2 threshold was used to mark the set of upregulated transcripts. In vitro probing of RNA secondary structure. We used a medium-throughput approach, based on PARS 37 , to probe the secondary structure of the given sRSE decoy sequence. Upon digestion and precipitation 37 of 1 mg of sRSE RNA, we used poly-A polymerase (NEB) for 15 min at 37 uC to add a poly-A tail to RNA fragments. We then used an oligo-dT primer linked to a KpnI site to make the firststrand cDNA (Superscript III, Invitrogen). A KpnI-linked 59 specific primer along with a reverse primer matching the reverse transcriptase primer was used to PCR amplify the cDNA fragments with intact 59 ends. The PCR product was then digested with KpnI and ligated (for concatenation) before cloning into KpnI digested pUC19 vector. Colonies were then randomly picked for each nuclease, and the 39 digestion sites were mapped through Sanger sequencing. mCherry/GFP reporter system. A Gateway (Invitrogen) destination vector was designed by cloning an R1-R2 gateway cloning site in the 39 UTR of mCherry in the pcDNA5/FRT backbone 38 (Invitrogen). A bi-directional promoter (pBI-CMV, Clontech) drives both mCherry and GFP (internal control) transcription (Extended Data Fig. 4b ). Oligonucleotides carrying different variants were PCR-amplified using primers linked to B1 and B2 sequences. BP Clonase enzyme mix (Invitrogen) was used to clone PCR products into pDONR-221 vector. LR Clonase (Invitrogen) was subsequently used to subclone the variants into the destination reporter construct. The reporters were then transiently transfected into MDA-LM2 cells and subjected to RNA extraction (Norgen Biotek RNA extraction kit), cDNA synthesis and qRT-PCR for both mCherry and GFP samples 48 h post-transfection as detailed previously 8 . Cells were seeded and transfected in biological replicates, and qPCR was performed in technical replicates. Technical replicates were averaged before statistical comparisons (performed using a one-tailed Mann-Whitney test). Identifying potential sRSE-binding proteins. We used a compendium of breast cancer gene expression profiles 14 to probe correlations between sRSE-carrying transcripts and putative RNA binding proteins. First, we focused on sRSE-carrying transcripts that were also destabilized in MDA-LM2 cells (differential decay rate score of less than 20.8) to enrich for functional sRSEs. Using a 'centroid linkage' k-means method, we then clustered the matrix of expression values across these transcripts to identify clusters with low intra-cluster and high inter-cluster distance as a core module. We then correlated the expression levels of putative/ validated double-stranded RNA-binding proteins to those of the identified cluster both individually and also as an aggregate (average of variance normalized values). The list of RNA-binding proteins with a significantly non-zero distribution of correlations (P , 0.01) and significant correlations with the aggregate profile was further narrowed down by selecting the candidates that displayed expression changes in the metastatic lines relative to their parental cells. Using these criteria, we identified TARBP2, HEXIM1 and PPRC1 as potential candidates that bind and regulate sRSE-carrying transcripts (Extended Data Fig. 4a ). We should highlight that this shortlist of candidate RBPs was not sensitive to the choice of regulon, method or data set. For example, a similar analysis performed for sRSE1-carrying transcripts, using the same criteria as described earlier, resulted in the identification of TARBP2, HEXIM1 and PPRC1 as potential candidates that bind and regulate sRSE1-carrying transcripts. Whole-genome measurements for TARBP2 modulations. For TARBP2, the following short interfering RNAs (siRNAs) were used (antisense strand): si1, UA CUGAAUUUCGUAGAGAAUCCCAGGU; si2, GCAGCAUAUUUAUUCCAG GCUCUAGUA; si3, GCUGAGGCUCUGUGGUCCUUGGCUCCU. Sequences 2 and 3 were used for MDA-LM2 and 1 and 2 for CN-LM1a. For HEXIM1 we used: UGAUUUAUUGAUUUGUGUAUGCUUCUU and GUCCUCUUCAGU UUGUAAUUCCUGCAG. For PPRC1, we used: UUCCACACAGGCUGCUGG CUGCUCCUU and AGAACUAGUCUCUAGCGAGUCAUCCAG. The siRNAs were transfected as described previously 8 . Total RNA was extracted (Norgen Biotek RNA extraction kit) 48 h post-transfection, and sufficient knockdown (.5-fold) was tested using qRT-PCR 8 . The samples were then labelled and hybridized as described earlier. The Lumi package in R was used to transform and normalize signal intensities. Each siRNA was counted as a biological replicate (two biological replicates per target gene) and BLOCK-iT Fluorescent Oligo (IDT), used as the control (siControl), was transfected in biological replicate and prepared in parallel. The logFC between average siRNA and siControl signal was used as a measure of differential expression for each transcript. For quantized analyses, a logFC .0.2 threshold was used to mark the set of upregulated transcripts.
Transcript stability was measured for siTARBP2 and siControl samples using a-amanitin (Sigma) as an inhibitor of RNA polymerase II 8 . Briefly, RNA from LETTER RESEARCH a-amanitin-treated cells was collected at 0 and 18 h and hybridized (as described earlier). The normalized transcript levels were then corrected based on the amount of labelled RNA achieved per unit of input total RNA. The ratio between average abundance (averaged between biological replicates) at 18 and 0 h samples was used as a measure of stability for each sample (all transfections were performed in biological replicates). The log-ratio between siTARBP2 and siControl samples was used to identify the transcripts that are stabilized in TARBP2 depleted cells. A cut-off of 0.32, which corresponds to ,10% of all transcripts, was used to mark the stabilized transcripts (Fig. 2b) . This step also ensures that the identified transcripts were not by-products of the 4sU methodology and can be recapitulated using RNA polymerase inhibitors.
For transient TARBP2 overexpression, we used a pCMV6-TARBP2 vector transfected into MDA-LM2 cells along with a pCMV6-GFP vector as control. Total RNA was extracted 72 h post-transfection, labelled, and hybridized as described earlier. The logFC between average pCMV6-TARBP2 and pCMV6-GFP signal was used as a measure of differential expression for each transcript. A logFC ,20.2 threshold was used to mark the set of downregulated transcripts. TARBP2 HITS-CLIP. HITS-CLIP was performed as previously described 39 with the following modifications. MDA-LM2 cells were transiently transfected with a vector expressing Myc-tagged TARBP2 (Origene). Forty-eight hours post-transfection, cells were crosslinked with 400 mJ cm 22 ultraviolet radiation. An anti-Myc antibody (Millipore 4A6 #05-724) was conjugated to protein G Dynabeads (Life Technologies) and used to immunoprecipitate the RNase-A-treated protein-RNA complexes. After calf intestinal phosphatase (CIP) treatment, the RNAs bound to the immunoprecipitated proteins were labelled with 32 P c-ATP by T4 polynucleotide kinase (PNK). After elution from the beads, the labelled protein-RNA complexes were resolved by SDS-PAGE and visualized by blotting onto a nitrocellulose membrane and exposing the membrane to film. After isolation from the nitrocellulose membrane, the RNA was prepared into a fourfold multiplexed Illumina compatible sequencing library using the Nextflex small RNA kit (Bioo Scientific). We sequenced low (1:3,000 dilution) and medium (1:1,500 dilution) RNase-A-treated samples and used the medium treatment samples for the results presented here. We used strand-specific ChIPseeqer 8, 40 to identify TARBP2-binding sites common between the two biological replicates. To correct for the peak positions obtained from single-end reads, we appended an additional 50 bp downstream of the identified peaks. We used a 1st order Markov model (provided as part of ChIPseeqer 40 ) to generate shuffled sequences from the identified binding sites. These randomized sequences were used as background for measuring the enrichment of sRSE instances among the identified sites. Similar to the case for the entire transcriptome, to find sRSE matches, we used TEISER in non-discovery mode to locate all potential instances of the entire family. In silico folding was then used to identify the sequence matches that also strictly followed the structural attributes. The set of these matches were defined as sRSEs, which were then used to measure enrichment among the binding sites. In parallel, we also used crosslinking-induced mutation sites (CIMS 41 ) to ensure that our findings were not sensitive to the choice of analytical pipeline. Similarly, we also used sRSE1 as the representative member of the family to run TEISER in nondiscovery mode on TARBP2-bound sequences. Identifying the TARBP2-bound transcripts. TARBP2-binding sites identified using strand-specific ChIPseeqer 8, 40 were used to obtain a comprehensive list of TARBP2-bound transcripts (,5,000 transcripts). We subsequently calculated the enrichment/depletion of this regulon in our whole-genome measurement data sets, namely: (1) differential stability measurements in MDA-LM2 versus MDA-231 cells, (2) expression and stability of transcripts in RNAi-mediated TARBP2 knockdown, and (3) expression in TARBP2 overexpression in MDA-LM2 cells. Western blotting. Cellular lysates were prepared by lysing cells (5-10 million) in ice-cold RIPA buffer containing protease and phosphatase inhibitors (Roche). Cellular debris was removed by centrifugation (12,000 r.p.m.) for 20 min at 4 uC. Samples were denatured in loading buffer, separated using SDS-PAGE, transferred to a PVDF membrane (Pierce), blocked, and probed using an anti-TARBP2 antibody (1:1,000; H00006895-PW1, Abnova). Bound antibodies were chemiluminescently detected using horseradish-peroxidase-conjugated secondary antibodies (1:10,000), ECL Western Blotting Substrate (Pierce) and the SRX-101A (Konica Minolta) developer, according to the manufacturer's instructions. The membrane was then stripped (Restore Western Blot Stripping Buffer, Pierce), re-probed (at room temperature for 1 h) and redeveloped (similar to the previous step) using an anti-tubulin antibody (1:1,000; Sigma) as an internal control. Analysis of TARBP2 transcript expression in cDNA arrays. Breast cancer TissueScan cDNA plates I and IV (Origene) were re-suspended in 44 ml of water. Ten microlitres of dissolved cDNA was quantified (in technical quadruplicate) for ACTB expression as per the manufacturer's instructions. Another 10 ml was used for TARBP2 quantification as described before 6 . 59-CAGGAGTATGGGACCA GAATAGG and ACCCGGAAGGTGAAATTAGGC were used as primers.
Metastatic colonization assays. Stable TARBP2 knockdown cells were generated by stable transfection and expression of shRNAs in MDA-LM2 and CN-LM1a lines. TARBP2 sh1 and sh2 in MDA-LM2 corresponds to TRCN0000019339 and TRCN0000330578 (Sigma) and in CN-LM1a to TRCN0000330642 and TRCN0000019339. In all cases, we achieved ,8-fold reduction in TARBP2 transcript levels measured using qRT-PCR. Seven-to-eight-week-old age-matched female NOD/SCID gamma mice (Jackson Labs) were used for lung metastasis assays 6 . In all cases, 2 3 10 4 cells in 100 ml PBS were injected via the tail vein along with cells expressing a neutral hairpin as control. Metastatic growth was tested using both a two-way analysis of variance (ANOVA) as a function of time and subline identity and also a Mann-Whitney-test-mediated comparison of area under the curve for each mouse. Histology. For gross macroscopic metastatic nodule visualization, three lungs from representative mice (from each cohort) were extracted ,30 days postinjection and 5-mm-thick lung tissue sections were haematoxylin and eosin (H&E) stained. The number of macroscopic nodules was then recorded for each section. An unpaired t-test and a Mann-Whitney test were used to test for significant variations. Cancer cell proliferation. Roughly 1 3 10 4 cells were seeded into three 6-well plates. They were subsequently trypsinized and viable cells were counted using a hemocytometer at days 1, 3 and 5. An exponential model was then used to fit a growth rate for each sample (ln(N t 2 1 /N 1 ) 5 rt where t is measured in days). The experiment was performed in biological quadruplicates and a one-tailed MannWhitney test was used to test for significant variations. Invasion assays. Invasion assays were performed as previously described 42 . For APP peptide pre-treatment, 100 ng of amyloid-a, amyloid-a* (304-612), or amyloidb (Sigma) were added to transwell invasion chambers (BD Biosciences) along with BSA (Sigma) as a control. Orthotopic metastasis. For orthotopic metastasis assay, we prepared 5 3 10 5 cells in 100 ml of a 1:1 mixture of PBS with matrigel and injected them into the mammary fat pad of 7-8-week-old NOD-SCID gamma female mice (the two bottom mammary fat pads in each mouse were used). After 1 week, wound clips were removed and tumour size was measured every 3 days beginning from day 20 postinjection to day 32. At day 32, tumours were extracted and 1 week later, metastases to the lungs were measured by bioluminescence imaging. The lungs were then extracted for ex vivo imaging. Tumour growth rates (day
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) were estimated based on an exponential model starting at day 20. Generating double-knockdown cell lines. The four TARBP2 targets (that is, APP, ZNF395, AP2A2 and LAMB1) were chosen based on the following criteria: higher expression and stability in MDA-LM2 TARBP2 knockdown (siRNA-mediated), downregulation in MDA-LM2 cells relative to the parental MDA line, and carrying significant tag clusters in TARBP2 HITS-CLIP. For each of the four targets, independent shRNAs expressed in pLKO.1-Blast vector were stably transfected into TARBP-sh1 in MDA-LM2 and TARBP2-sh1 in CN-LM1a (which correspond to different hairpins as mentioned earlier). For the secondary hairpin, we used TRCN0000381611, TRCN0000183104, TRCN0000006705 and TRCN0000083428 in the MDA-LM2-shTARBP2 background and used TRCN0000065123, TRCN0000184700, TRCN0000006706 and TRCN0000083429 in the CN-LM1a-shTARBP2 subline. Double knockdowns were subsequently validated using qRT-PCR. A control hairpin in pLKO.1-Blast was used as the reference. These sublines were subsequently used for in vivo colonization assays, histology and in vitro invasion assays upon validating sufficient (.3-fold) knockdown in the targeted transcripts. Clinical associations. For the aggregate target gene-signature, that is, APP, ZNF395, AP2A2 and LAMB1, we used a compendium of breast cancer gene expression data sets (BR comp.) 19 to generate Kaplan-Meier curves. For the APP-ZNF395 combined signature, GEO accession GSE25066 (ref. 43) was also used, which records survival after taxane-anthracycline chemotherapy to highlight that the association of these genes were not remedied by chemotherapy. The P values were calculated using a one-tailed log-rank test. For association between expression and tumour grade, we used three independent data sets-GEO accessions GSE5460 (ref. 44 ), GSE2109 and the breast cancer compendium mentioned earlier-to stratify tumours based on BR grades (high versus low) and employed a one-tailed Mann-Whitney test to calculate the associated P values. Gene expression profiling of ZNF395 knockdown. Total RNA samples from shZNF395 and shControl in an MDA-LM2-shTARBP2 background were prepared for hybridization as detailed before (in quadruplicates). Statistics and animal studies. All animal work was conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee at The Rockefeller University. As mentioned earlier, animal experiments were performed in cohorts of approximately five mice each. This number has been previously shown to provide sufficient power to detect larger than twofold changes in metastatic burden in the lungs. Independent cell lines and hairpins were used to ensure RESEARCH LETTER that the observed effects were neither cell-line specific nor due to off-target effects. Criteria for exclusion included accidental death before the completion of the experiment for causes unrelated to the experiment (for example, death due to injection). A two-way ANOVA and a one-tailed Mann-Whitney were used to compare cohorts (as described earlier). No blinding was used for the animal studies. Mice were randomly assigned to the sample and control cages before injections.
The statistical tests used to compare samples and cohorts in this study are previously described and well-established. In cases in which a parametric t-test was used, we first checked normality using a Shapiro-Wilk normality test or a KS normality test (depending on the number of measurements available). We were cautious in making as few assumptions as possible in our data analysis, often using non-parametric and/or multiple statistical tests for each experiment/analysis. Data availability. Raw data sets are deposited in the GEO database under accession number GSE49649. The processed files and associated results are also available at https://tavazoielab.c2b2.columbia.edu/TBSE; TEISER is available at https:// tavazoielab.c2b2.columbia.edu/TEISER.
Extended Data Figure 1 | The sRSE family of structural cis-regulatory RNA elements is enriched in transcripts exhibiting reduced stability in metastatic MDA-LM2 cells. a, The sRSE family is composed of 318 GC-rich structural elements with sRSE1 serving as the most informative representative. These elements were enriched in the transcripts destabilized in MDA-LM2 cells. Here, we have included a subset of structural elements that reside in this family. These motifs display a lower statistical significance relative to sRSE1 and have a conditional information ratio of less than 2.0 with respect to sRSE1; in other words, these motifs form an overlapping family of structural elements for which sRSE1 is the best representative. For the analyses presented in this study, we have provided enrichment/depletion patterns for the entire sRSE family as well as sRSE1 as the representative. b, sRSE1 was significantly enriched in transcripts downregulated in MDA-LM2 cells relative to the parental population.
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Extended Data Figure 4 | Identification of TARBP2 as the potential modulator of the sRSE regulon and the regulatory consequences of TARBP2 modulations. a, Three RBPs, TARBP2, HEXIM1 and PPRC1, were selected as potential regulators of the sRSE regulon on the basis of their positive/negative correlations with this regulon at the transcript level (Methods). Here, the Spearman correlations (and their associated t-statistics) between the sRSE target signature and each of the candidate RBPs have been shown. We have also included the distribution of Spearman correlations for each candidate RBP along with the associated P values (see Methods). b, Unlike TARBP2, RNAimediated knockdown of PPRC1 and HEXIM1 did not result in a significant deregulation of the sRSE-carrying transcripts. c, In addition to MDA-LM2 cells, a significant increase in the expression sRSE-carrying transcripts was also observed in RNAi-mediated TARBP2 knockdown cells in CN-LM1a and 293T backgrounds. d, The sRSE1 motif showed a similar enrichment pattern to that of the entire sRSE family with significant overrepresentations among the transcripts upregulated upon TARBP2 silencing in both CN-LM1a and 293T backgrounds. e, f, The enrichment/depletion patterns of sRSE1-carrying transcripts, as representative of the sRSE family, in transcript stability and gene expression profiles of cells in which TARBP2 levels were modulated. g, Linear regression analysis of gene-expression profiles from TARBP2 siRNA knockdown and sRSE1 in-culture cellular titration experiments. The smoothed density at each point in the scatterplot has been shown as a colour map. The P value represents the significance of the reported Spearman correlation (Rho).
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Extended Data Figure 5 | TARBP2 directly interacts with and modulates the sRSE regulon in vivo. a, TARBP2 HITS-CLIP results were significantly correlated between the two replicates. b, TARBP2-bound sequences (determined by HITS-CLIP) were annotated and presented as a pie chart. The majority of interactions were intronic; however, direct interactions with exons, small nucleolar/microRNAs and long non-coding (lnc)RNAs were also observed. c, Crosslinking-induced mutation sites (CIMS) analysis of TARBP2 HITS-CLIP data (Methods), similar to the results obtained from ChIPseeqeridentified binding sites, also showed an enrichment of the sRSE family in the TARBP2-binding site relative to their shuffled counterparts (1st order Markov model; see Methods). d, Similar to the case for the entire sRSE family, sRSE1 was also significantly enriched among the TARBP2-binding sites identified by ChIPseeqer and CIMS respectively. e, We observed a highly significant overlap between transcripts that we identified as direct interacting partners of TARBP2 (using HITS-CLIP; see Methods) and the sRSE-carrying transcripts (53% overlap, hypergeometric P-value ,10
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). f, The TARBP2 HITS-CLIP clusters, identified as the CIMS common between the two biological replicates, were folded in silico and the resulting terminal stem-loops were extracted. Consistent with the GC-rich nature of sRSE elements, these stem-loops displayed a significant shift towards higher GC contents. The associated P value was calculated using a Wilcoxon rank-sum test with m 5 0.45 (GC content of annotated genes in human genome marked by the light blue line) as the null hypothesis. g, In silico folding of the identified TARBP2 CIMS binding sites (Vienna RNA Package 45 ) displayed more stable secondary structures formed by real sequences relative to their shuffled counterparts (1st order Markov model). The associated P value was calculated using a paired Mann-Whitney test between free-energy estimates for real and shuffled sequences. h, The relative stability of sRSE1/scrambled-fused mCherry reporters assayed in control and TARBP2 knockdown cells. Samples in quadruplicate were treated with a-amanitin and total RNA was extracted at the 0 and 8 h time points. Following DNase digestion and cDNA synthesis, transcript levels were quantified using qPCR in order to measure relative stability for mCherry (with GFP as the endogenous control). Error bars indicate s.e.m. *P , 0.05 using a MannWhitney test. i, j, In this study, we initially used the sRSE family as a proxy to track the behaviour of a broader regulon. Upon identification of TARBP2 as the trans factor, however, we could directly assess the targets that are bound by TARBP2 in vivo. As shown here, consistent with our previous observations, these transcripts showed an enrichment pattern identical to that of sRSEcarrying transcripts: they are enriched among the transcripts that are downregulated/destabilized in MDA-LM2 cells, upregulated and stabilized in TARBP2-knockdown cells, and downregulated when TARBP2 is overexpressed. We observed similar upregulations upon TARBP2 knockdown in CN-LM1a and 293T cells. These observations further support the coherence of our findings and the use of sRSE as a surrogate for probing this regulon.
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Extended Data Figure 7 | TARBP2 silencing suppresses metastatic colonization and results in fewer metastatic nodules formed in the lungs of xenografted mice. a, Western blots were performed for TARBP2 in MDA, LM2, CN34 and LM1a cells using tubulin as an internal control. TARBP2 relative protein abundance was then quantified with each sample measured in triplicate. Quantification was performed using ImageJ. Statistical significance was assessed using a Mann-Whitney test (*P 5 0.05). b, Relative expression levels of TARBP2 mRNA in metastatic (stage IV) tumours compared to early stage (stages I and II) tumours (n 5 59; see Methods). Error bars indicate s.e.m. *P , 0.05 by a one-tailed Student's t-test. c, Bioluminescence imaging plot of lung metastasis by MDA-LM2 cells expressing shRNAs targeting TARBP2 (shTARBP2) or a control hairpin (shControl); n 5 5 and 6, respectively. The area under the curve was also calculated for each mouse. *P , 0.05, **P , 0.01, ***P , 0.001 by a Student's t-test unless specified otherwise. d, Haematoxylin and eosin (H&E)-stained images of representative lung sections from a tailvein-injected mouse cohort extracted at day 33 post-injection (Fig. 3b) . e, In vitro proliferation rates (day
21
) for cells expressing shControl or TARBP2 shRNAs (n 5 4 for each sample). f, Cell invasion capacity of MDA-LM2 cells quantified upon transwell matrigel invasion assays; n 5 8 for each sample comparing shTARBP2 to shControl cells (two independent sets of biological quadruplicates). Also shown are representative images of transwell inserts along with the median count (m) for each experiment. **P , 0.01 by a onesample Mann-Whitney test. g, Lung bioluminescence (7 days after tumour extraction) measured upon extraction ex vivo (n 5 3 for shControl and 4 for shTARBP2 cohorts). Error bars in all panels indicate s.e.m. unless otherwise specified. *P , 0.05, **P , 0.01, ***P , 0.001 by a one-tailed Mann-Whitney test unless specified otherwise.
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